AR077611A1 - Metodo y conjunto de elementos ( kit) para tratar la adiccion a la nicotina. combinacion. uso. - Google Patents
Metodo y conjunto de elementos ( kit) para tratar la adiccion a la nicotina. combinacion. uso.Info
- Publication number
- AR077611A1 AR077611A1 ARP100102769A ARP100102769A AR077611A1 AR 077611 A1 AR077611 A1 AR 077611A1 AR P100102769 A ARP100102769 A AR P100102769A AR P100102769 A ARP100102769 A AR P100102769A AR 077611 A1 AR077611 A1 AR 077611A1
- Authority
- AR
- Argentina
- Prior art keywords
- nicotine
- subject
- antibodies
- combination
- receptor agonist
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0013—Therapeutic immunisation against small organic molecules, e.g. ***e, nicotine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39583—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials not provided for elsewhere, e.g. haptens, coenzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Addiction (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Reivindicacion 1: Un método para tratar la adiccion a la nicotina en un sujeto, caracterizado porque comprende: (a) inducir un nivel umbral de anticuerpos anti-nicotina en un sujeto mediante la administracion de una o más entre (i) una composicion inmunogénica de nicotina y (ii) una composicion que comprende anticuerpos anti-nicotina; y (b) administrar una serie de un agonista del receptor de nicotina o un antagonista del receptor de nicotina al sujeto; en donde el nivel umbral de anticuerpos anti-nicotina se obtiene en el sujeto al momento que se completa la serie de un agonista del receptor de nicotina o antagonista del receptor de nicotina. Reivindicacion 31: Una combinacion, caracterizada porque comprende (a) una o más entre (i) una composicion inmunogénica de nicotina y (ii) una composicion de anticuerpos anti-nicotina, y (b) un agonista del receptor de nicotina o un antagonista del receptor de nicotina, para su uso en el tratamiento de adiccion a la nicotina en un sujeto, en donde la composicion inmunogénica de nicotina y/o la composicion de anticuerpos anti-nicotina se administran para inducir un nivel umbral de anticuerpos anti-nicotina en el sujeto, y una serie de un agonista del receptor de nicotina o un antagonista del receptor de nicotina se administra de manera simultánea o sucesiva con la composicion inmunogénica de nicotina y/o la composicion de anticuerpos anti-nicotina, en donde el nivel umbral de anticuerpos anti-nicotina se obtiene en el sujeto al momento que se completa la serie de un agonista del receptor de nicotina o de un antagonista del receptor de nicotina. Reivindicacion 44: La combinacion de cualquiera de las reivindicaciones 31-43, caracterizada porque la composicion inmunogénica de nicotina comprende un conjugado de transportador de nicotina que comprende 3'-aminometilnicotina conjugado con una proteína transportadora adecuada. Reivindicacion 45: La combinacion de cualquiera de las reivindicaciones 31-44, caracterizada porque el agonista del receptor de nicotina o el antagonista del receptor de nicotina comprende vareniclina. Reivindicacion 48: La combinacion de cualquiera de las reivindicaciones 31-47, caracterizada porque el agonista del receptor de nicotina o el antagonista del receptor de nicotina comprende bupropion.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US23030109P | 2009-07-31 | 2009-07-31 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR077611A1 true AR077611A1 (es) | 2011-09-07 |
Family
ID=42830360
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP100102769A AR077611A1 (es) | 2009-07-31 | 2010-07-29 | Metodo y conjunto de elementos ( kit) para tratar la adiccion a la nicotina. combinacion. uso. |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20110064750A1 (es) |
| EP (1) | EP2459215A1 (es) |
| JP (1) | JP2013500988A (es) |
| AR (1) | AR077611A1 (es) |
| TW (1) | TW201109031A (es) |
| WO (1) | WO2011014679A1 (es) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2009257547A1 (en) * | 2008-06-13 | 2009-12-17 | Nabi Biopharmaceuticals | Smoking cessation kit and method |
| US20110182918A1 (en) | 2008-06-13 | 2011-07-28 | Nabi Biopharmaceuticals | Personalized drug treatment and smoking cessation kit and method |
| SI2759306T1 (sl) * | 2008-12-09 | 2016-05-31 | Coley Pharmaceutical Group, Inc. | Imunostimulacijski oligonukleotidi |
| WO2011123042A1 (en) * | 2010-04-01 | 2011-10-06 | Independent Pharmaceutica Ab | Vaccination procedure and products for use therein |
| WO2016133890A1 (en) * | 2015-02-19 | 2016-08-25 | Srq Patent Holdings, Llc | Compositions for e-cigarettes |
| US10639327B1 (en) | 2015-11-20 | 2020-05-05 | Washington University | Nano-calcium carbonate |
| AU2017293925B2 (en) * | 2016-07-07 | 2022-02-03 | Howard Hughes Medical Institute | Modified ligand-gated ion channels and methods of use |
| SG11202004246YA (en) | 2017-11-10 | 2020-06-29 | Hughes Howard Med Inst | Modified ligand-gated ion channels and methods of use |
| JP2021526529A (ja) * | 2018-06-06 | 2021-10-07 | アンティドートゥ・セラピューティクス・インコーポレイテッド | 循環を改善するおよび心血管疾患を治療するための方法 |
| WO2020023792A1 (en) * | 2018-07-27 | 2020-01-30 | Amygdala Neurosciences, Inc. | Combination therapy for nicotine addiction |
| WO2023244584A1 (en) | 2022-06-14 | 2023-12-21 | Amygdala Neurosciences, Inc. | Aldh-2 inhibitor compounds and methods of use |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5876727A (en) | 1995-03-31 | 1999-03-02 | Immulogic Pharmaceutical Corporation | Hapten-carrier conjugates for use in drug-abuse therapy and methods for preparation of same |
| US6232082B1 (en) * | 1998-12-01 | 2001-05-15 | Nabi | Hapten-carrier conjugates for treating and preventing nicotine addiction |
| US7052854B2 (en) * | 2001-05-23 | 2006-05-30 | University Of Florida Research Foundation, Inc. | Application of nanotechnology and sensor technologies for ex-vivo diagnostics |
| BR0312297A (pt) * | 2002-07-18 | 2005-04-12 | Cytos Biotechnology Ag | Conjugados veìculos de hapteno e seu uso |
| WO2007064478A2 (en) | 2005-11-28 | 2007-06-07 | Nabi Biopharmaceuticals | Method for making nicotine hapten |
| AU2009257547A1 (en) * | 2008-06-13 | 2009-12-17 | Nabi Biopharmaceuticals | Smoking cessation kit and method |
| US20110182918A1 (en) * | 2008-06-13 | 2011-07-28 | Nabi Biopharmaceuticals | Personalized drug treatment and smoking cessation kit and method |
-
2010
- 2010-07-29 EP EP10742944A patent/EP2459215A1/en not_active Withdrawn
- 2010-07-29 US US12/846,514 patent/US20110064750A1/en not_active Abandoned
- 2010-07-29 JP JP2012523048A patent/JP2013500988A/ja active Pending
- 2010-07-29 WO PCT/US2010/043748 patent/WO2011014679A1/en active Application Filing
- 2010-07-29 AR ARP100102769A patent/AR077611A1/es unknown
- 2010-07-29 TW TW099125220A patent/TW201109031A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20110064750A1 (en) | 2011-03-17 |
| WO2011014679A1 (en) | 2011-02-03 |
| EP2459215A1 (en) | 2012-06-06 |
| TW201109031A (en) | 2011-03-16 |
| JP2013500988A (ja) | 2013-01-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR077611A1 (es) | Metodo y conjunto de elementos ( kit) para tratar la adiccion a la nicotina. combinacion. uso. | |
| CY1122060T1 (el) | Συνδυαστικη θεραπευτικη χρηση αντισωματων και ενδογλυκοσιδασεων | |
| EA200601761A1 (ru) | Композиции в качестве адъювантов для усиления иммунных ответов на вакцины и способы их применения | |
| AR109605A2 (es) | Método para tratar enfermedades vasculares periféricas, composición y utilización | |
| AR107303A1 (es) | Métodos de tratamiento de cánceres positivos para ace utilizando antagonistas de unión a eje pd-1 y anticuerpos biespecíficos anti-ace / anti-cd3, uso, composición, kit | |
| AR064363A1 (es) | Tratamiento de cerdos con el antigeno pcv | |
| AR090294A1 (es) | Composiciones de neisseria meningitidis y metodos de las mismas | |
| CY1109877T1 (el) | Αντισωματα εναντι αμυλοειδους-βητα πεπτιδιου | |
| EA200700175A1 (ru) | Композиции и способы лечения воспалительных заболеваний | |
| AR064725A1 (es) | Profilaxis y tratamiento del complejo respiratorio porcino (prdc). uso | |
| EA201290964A1 (ru) | Пептидные конъюгаты агонистов рецептора glp-1 и их применение | |
| CO6331425A2 (es) | Composiciones que comprenden n-(3,4-difluoro-2-(2-fluoro-4-yodofenilamino)6-metoxifenil)-1-(2,3-dihidroxiproxipropil)ciclopropan-1-sulfamida | |
| PE20110023A1 (es) | Composiciones inmunogenicas de antigenos de staphylococcus aureus | |
| CL2012000520A1 (es) | Anticuerpo o fragmento de union a antigeno del mismo capaz de unirse a dll4 humana; conjugado que comprende a dicho anticuerpo; vector aislado y celula huesped; metodo para producir dicho anticuerpo; composicion farmaceutica que lo comprende; y uso medico de dicho anticuerpo. | |
| UA109633C2 (uk) | Антитіло людини проти тканинного фактора | |
| UA116871C2 (uk) | СПОСІБ ЛІКУВАННЯ МІЄЛОДИСПЛАСТИЧНОГО СИНДРОМУ, ТАЛАСЕМІЇ ТА СЕРПОПОДІБНО-КЛІТИННОЇ АНЕМІЇ ЗА ДОПОМОГОЮ ЗАСТОСУВАННЯ АНТАГОНІСТА АКТИВІНУ ПОЛІПЕПТИДУ ActRII | |
| DK2719708T3 (da) | Materiale og fremgangsmåder til behandling eller forebyggelse af her-3-relaterede sygdomme | |
| AR085633A1 (es) | Coadyuvantes basados en anticuerpos que son dirigidos directamente a las celulas presentadoras en antigenos | |
| CO6410314A2 (es) | Proteínas de unión a il-17 | |
| EA201301072A1 (ru) | Антитела против il-23p19 и их применение | |
| AR074777A1 (es) | Proteinas de union a antigeno | |
| EA201071291A3 (ru) | Nmda рецепторные антагонисты для лечения нейропсихиатрических расстройств | |
| GT200800098A (es) | Anticuerpos anti mn y metodos para su utilización | |
| PE20142332A1 (es) | Metodo y formulacion para reducir la agregacion de una macromolecula bajo condiciones fisiologicas | |
| PE20140190A1 (es) | Moduladores de proteinas notum y metodos de uso |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |